Definition & Mechanism

  • Glucarpidase is a recombinant bacterial enzyme (carboxypeptidase G2) used as a rescue agent to rapidly lower toxic plasma methotrexate levels in patients with impaired renal function.
  • It works by hydrolyzing methotrexate into inactive metabolites (glutamate and DAMPA), providing a non-renal pathway for methotrexate elimination.

Indication

Administration

  • Given as a single intravenous injection (50 units/kg) over 5 minutes.
  • Should be used in conjunction with leucovorin, but leucovorin must be administered at least 2 hours before or after glucarpidase to avoid inactivation.

Key Clinical Points

  • Rapid Action: Reduces plasma methotrexate levels by >95% within 15 minutes in most patients.
  • Not for Routine Use: Only for patients with toxic methotrexate levels and impaired renal clearance; not for those with normal or mildly impaired renal function.
  • Monitoring: Methotrexate assays may be unreliable after glucarpidase due to cross-reactivity with DAMPA; use chromatographic methods for accurate measurement.
  • Adverse Effects: Generally well tolerated; hypersensitivity reactions are rare.
  • No Dose Adjustment: Not required for renal or hepatic impairment.

Summary Table

Aspect Key Point
Mechanism Enzymatic hydrolysis of methotrexate to inactive metabolites
Indication Toxic methotrexate levels with renal dysfunction
Administration IV injection, 50 units/kg, single dose
Use with Leucovorin Separate by at least 2 hours
Monitoring Use chromatographic assays for methotrexate post-glucarpidase
Major Toxicities Rare; hypersensitivity possible

Glucarpidase is a critical rescue agent for oncology patients with life-threatening methotrexate toxicity and renal impairment, enabling rapid drug clearance and reducing the risk of severe toxicity.

Comparison for Oncology Pharmacy Practice

Feature Calcium Folinate Glucarpidase
Primary Function Cellular folate rescue Plasma MTX elimination
Lowers serum MTX? ❌ No ✅ Yes (rapidly)
Works intracellularly? ✅ Yes ❌ No
Role in routine HD-MTX? Standard of care Not routine
Role in MTX-induced AKI? Supportive but insufficient alone Definitive rescue
Timing sensitivity Critical Emergency use in delayed clearance
Cost Low Extremely high
Impact on MTX efficacy Can reduce if overdosed No direct effect on tumor intracellular MTX
 

 

 
 
Links